KR20230039718A - 보체 인자 c3의 억제제 및 이들의 의학적 용도 - Google Patents

보체 인자 c3의 억제제 및 이들의 의학적 용도 Download PDF

Info

Publication number
KR20230039718A
KR20230039718A KR1020237005557A KR20237005557A KR20230039718A KR 20230039718 A KR20230039718 A KR 20230039718A KR 1020237005557 A KR1020237005557 A KR 1020237005557A KR 20237005557 A KR20237005557 A KR 20237005557A KR 20230039718 A KR20230039718 A KR 20230039718A
Authority
KR
South Korea
Prior art keywords
compstatin analog
pharmaceutically acceptable
compstatin
disease
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237005557A
Other languages
English (en)
Korean (ko)
Inventor
안네 페르닐레 토프텡 쉘톤
헨드릭 피셔 뭉크
라스무스 레트
Original Assignee
제트피 에스피브이 3 케이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제트피 에스피브이 3 케이/에스 filed Critical 제트피 에스피브이 3 케이/에스
Publication of KR20230039718A publication Critical patent/KR20230039718A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
KR1020237005557A 2020-07-16 2021-07-15 보체 인자 c3의 억제제 및 이들의 의학적 용도 Ceased KR20230039718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
EP20186297.6 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
KR20230039718A true KR20230039718A (ko) 2023-03-21

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005557A Ceased KR20230039718A (ko) 2020-07-16 2021-07-15 보체 인자 c3의 억제제 및 이들의 의학적 용도

Country Status (11)

Country Link
US (1) US20230287051A1 (cg-RX-API-DMAC10.html)
EP (1) EP4182023A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023538807A (cg-RX-API-DMAC10.html)
KR (1) KR20230039718A (cg-RX-API-DMAC10.html)
CN (1) CN116209671A (cg-RX-API-DMAC10.html)
AU (1) AU2021309548A1 (cg-RX-API-DMAC10.html)
CA (1) CA3185730A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001411A2 (cg-RX-API-DMAC10.html)
IL (1) IL299870A (cg-RX-API-DMAC10.html)
MX (1) MX2023000679A (cg-RX-API-DMAC10.html)
WO (1) WO2022013374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017385A2 (pt) 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品
CN122255228A (zh) * 2024-12-20 2026-06-23 重庆派金生物科技有限公司 靶向抑制c3与c5补体的双功能多肽、多肽偶联物及它们的应用
US20260234189A1 (en) 2025-01-24 2026-08-13 Boehringer Ingelheim International Gmbh Novel and stable compstatin analogues

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2751161B1 (en) * 2011-08-31 2018-09-19 Huntsmann Advanced Materials Licensing (Switzerland) GmbH Process for the impregnation of air core reactors, impregnated air core reactor and use of an impregnation system
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
ES3049784T3 (en) * 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
US20230287051A1 (en) 2023-09-14
CA3185730A1 (en) 2022-01-20
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CO2023001411A2 (es) 2023-02-16
CN116209671A (zh) 2023-06-02
JP2023538807A (ja) 2023-09-12
WO2022013374A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
IL299870A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
US12600749B2 (en) Compstatin analogues and their medical uses
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
JP7711044B2 (ja) コンプスタチン類似体及びその医学的使用
AU2018210174B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2020128443A (ja) インターロイキン23受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
BR112016008996B1 (pt) Ligante peptídico específico para calicreína plasmática e composição farmacêutica
CA2953721A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체
US10421785B2 (en) Delta receptor agonist peptides and use thereof
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине
HK40092906A (en) Inhibitors of complement factor c3 and their medical uses
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
HK40102364A (en) Compstatin analogues and their medical uses
HK40102364B (en) Compstatin analogues and their medical uses
US20210238229A1 (en) Peptide for disease treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601